In patients with atrial fibrillation, after a short period of triple therapy up to 1 week from the acute event, 1-year combination therapy with direct oral anticoagulant (DOAC) and P2Y12 inhibitor, followed by DOAC/novel oral anticoagulant (NOAC) monotherapy could be recommended, but for high thrombotic risk patients, a period of triple therapy might be extended to 3–6 months [21, 190]. This evidence concerns the gene P2RY12 and atrial fibrillation.